Arca
Skip to content

Liver transplantation

Drug research and approvals for liver transplantation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 195 studies of liver transplantation are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 1 approved and 6 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 195
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 195 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Apr 8, 2026Expanded antimicrobial prophylaxis to reduce surgical site infections in liver transplant recipientsMEROPENEM / VANCOMYCIN / DAPTOMYCIN / FLUCONAZOLEUNIVERSITY HEALTH NETWORKOngoing
Mar 10, 2022The glp-1 agonist semaglutide for the treatment of metabolic disease in liver transplant recipients: a phase IV, randomized trialSEMAGLUTIDE/ SITAGLIPTINUNIVERSITY HEALTH NETWORKPending
Feb 24, 2015Randomized controlled trial of ex vivo oxygenated, normothermic liver perfusion (organox metra) compared to standard cold storage in clinical liver…SOLUTION TO SUPPORT ORGANOX METRA PERFUSION SYSTEMGOVERNORS OF THE UNIVERSITY OF ALBERTAPending
Dec 16, 2014A multicenter treatment protocol for daclatasvir (bms-790052) in combination with sofosbuvir for the treatment of post-liver transplant subjects with chronic…DACLATASVIR (BMS-790052)/ SOFOSBUVIRBristol-Myers SquibbPending
Apr 15, 2014Assessing the safety and efficacy of a portable ex vivo oxygenated, normothermic liver perfusion system (organox metra) prior to liver transplantationSOLUTION TO SUPPORT ORGANOX METRA PERFUSION SYSTEMGOVERNORS OF THE UNIVERSITY OF ALBERTAOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Apr 6, 2007HepaGam BPrevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patientsCangene CorporationApproved
Mar 6, 2026tegoprubartprevention of allograft rejection in liver transplantationEledon Pharmaceuticals, Inc.Designated
Feb 15, 2022bucillaminePrevention of ischemia-reperfusion injury during liver transplantationRevive Therapeutics Inc.Designated
May 6, 2013hepatitis B virus neutralizing human monoclonal antibodyPrevention of hepatitis B recurrence following liver transplantationGreen Cross Corp.Designated
Jan 10, 2005(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hept…Prevention of acute rejection following kidney, heart, and liver transplantationAstellas Pharma US, Inc.Designated
Jul 15, 2003Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab…For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantationCubist PharmaceuticalsDesignated
Jun 17, 1991Monoclonal antibody to hepatitis B virus (human)Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.Protein Design Labs, Inc.Designated

Medicines Authorised in the EU

Newest first
Dec 8, 2017Tacforiustacrolimus · genericTeva B.V.EMA ↗
Nov 30, 2009Zutectrahuman hepatitis B immunoglobulinBiotest Pharma GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.